Chang Ung-Kyu, Kim Mi-Sook, Han Chul Ju, Lee Dong Han
Department of Neurosurgery, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Science, Nowon-ro 75, Nowon-ku, Seoul, 139-706, Republic of Korea,
J Neurooncol. 2014 Aug;119(1):141-8. doi: 10.1007/s11060-014-1463-9. Epub 2014 May 7.
We investigated the clinical outcome following stereotactic radiosurgery (SRS) for spinal metastasis from hepatocellular carcinoma (HCC) and compared it with that of conventional radiation therapy (cRT). Thirty-nine metastatic spine tumors from 27 HCC patients were treated with SRS from 2002 to 2011. Their medical records and radiological data were retrospectively analyzed. Median tumor volume was 49.7 cc, and a mean marginal dose of 28.7 Gy was delivered to the tumor mass. We analyzed overall survival (OS), local progression-free survival, and the rate of pain control following SRS. Factors relating to clinical outcomes were also investigated. Clinical results following cRT were obtained from 32 patients. The cRT protocol consisted of 30 Gy in 10 fractions or 39 Gy in 13 fractions. OS and local progression-free survival were compared between SRS and cRT. OS was a median of 7 months following SRS. Significant prognostic factors relating to OS included Child-Pugh class and Karnofsky performance scale. Tumor recurrence was noted in nine lesions during follow-up. The median local progression-free survival was 7 months. Previous irradiation was a significant prognostic factor for local recurrence (P = 0.043). The overall pain control rate was 85 % and no factors were found to be significantly correlated with the pain control rate. The median OS was 3 months in the cRT group and 7 months in the SRS group (P = 0.035). The median local progression-free survival was 2.0 months in the cRT group, and 7.0 months in the SRS group, which were significantly different (P = 0.033). SRS showed better local control than cRT in the treatment of HCC spinal metastasis.
我们研究了立体定向放射外科(SRS)治疗肝细胞癌(HCC)脊柱转移瘤后的临床结果,并将其与传统放射治疗(cRT)的结果进行比较。2002年至2011年期间,对27例HCC患者的39个脊柱转移瘤进行了SRS治疗。对他们的病历和放射学数据进行了回顾性分析。肿瘤中位体积为49.7立方厘米,肿瘤肿块的平均边缘剂量为28.7 Gy。我们分析了SRS后的总生存期(OS)、局部无进展生存期和疼痛控制率。还研究了与临床结果相关的因素。cRT的临床结果来自32例患者。cRT方案包括10次分割给予30 Gy或13次分割给予39 Gy。比较了SRS和cRT之间的OS和局部无进展生存期。SRS后的OS中位值为7个月。与OS相关的显著预后因素包括Child-Pugh分级和卡诺夫斯基功能状态评分。随访期间在9个病灶中发现肿瘤复发。局部无进展生存期的中位值为7个月。既往放疗是局部复发的显著预后因素(P = 0.043)。总体疼痛控制率为85%,未发现与疼痛控制率显著相关的因素。cRT组的OS中位值为3个月,SRS组为7个月(P = 0.035)。cRT组的局部无进展生存期中位值为2.0个月,SRS组为7.0个月,差异有统计学意义(P = 0.033)。在治疗HCC脊柱转移瘤方面,SRS显示出比cRT更好的局部控制效果。